ArticleJACC. Case reports2025
Stellate Ganglion Block to Increase Defibrillation Effectiveness in Acute Fulminant Myocarditis-Induced Refractory Ventricular Fibrillation.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and predictors of major arrhythmic events after myocarditis: a systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Pooled it
- Advances in the clinical application of stellate ganglion block for non-pain indications.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPercutaneous left stellate ganglion block (PLSGB) is used to prevent ventricular arrhythmia recurrences in various settings. Clinical data on its impact on ventricular fibrillation (VF) defibrillation threshold are scant and limited to acute coronary syndromes. CASE SUMMARY: We present a case of refractory VF in acute fulminant myocarditis. Despite multiple drugs and hemodynamic mechanical support, the VF was unresponsive to several DC shock attempts, including double sequential and vector change defibrillation. PLSGB allowed stable sinus rhythm restoration. DISCUSSION: PLSGB was performed to enhance the success of DC shock, highlighting the importance of acute neuromodulation strategies not only to prevent ventricular arrhythmia recurrences but also to improve defibrillation effectiveness. Our case is the first reported PLSGB usage in acute fulminant myocarditis-induced refractory VF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.